As the field of preclinical research continues to advance, the Cro industry plays a crucial role in supporting the development of new therapies and treatments. In this blog post, we will explore the latest statistics and trends in the preclinical Cro industry, shedding light on key insights and innovations shaping the future of drug discovery and development.
The Latest Preclinical Cro Industry Statistics Explained
The global preclinical contract research organization (CRO) market is estimated to reach USD 6.4 Billion by 2027 at a CAGR of 6.9%.
This statistic indicates that the global preclinical contract research organization (CRO) market is projected to grow significantly, reaching a value of USD 6.4 billion by the year 2027. The Compound Annual Growth Rate (CAGR) of 6.9% suggests a steady and healthy growth rate over the forecast period. This growth is likely driven by factors such as increased outsourcing of preclinical research activities by pharmaceutical and biotechnology companies, the growing emphasis on research and development in the life sciences industry, and advancements in technology and techniques within the preclinical CRO sector. Overall, the projected market growth reflects a trend towards greater reliance on external expertise and services in preclinical research to expedite drug discovery and development processes.
By 2025, the Oncology segment is expected to dominate the preclinical CRO market.
The statistic indicates that by the year 2025, the field of Oncology is projected to have the highest market share within the preclinical Contract Research Organization (CRO) industry. This forecast suggests that the demand for preclinical services related to Oncology research, such as drug development, efficacy testing, and toxicity studies, is likely to be the largest among all therapeutic areas. This dominance could be driven by various factors including the rising incidence of cancer worldwide, the growing investment in oncology research and development, and the increasing emphasis on personalized medicine in cancer treatment. As a result, companies operating in the preclinical CRO market may need to adapt their services and capabilities to cater to the specific needs and requirements of the Oncology segment in order to remain competitive and capture the opportunities presented by this trend.
The bioanalysis and DMPK studies service segment accounted for the largest share (24.5%) of the overall preclinical CRO services market in 2019.
In 2019, the bioanalysis and DMPK (Drug Metabolism and Pharmacokinetics) studies service segment represented the largest portion of the preclinical Contract Research Organization (CRO) services market, contributing 24.5% of the total market share. This indicates that a substantial proportion of the preclinical CRO services provided in that year were focused on bioanalysis and DMPK studies, which are crucial aspects of drug development and research. The prominence of this segment suggests a high demand for services related to analyzing drug levels in biological samples and understanding the pharmacokinetic properties of drug compounds, underscoring the significance of these studies in the pharmaceutical and biotech industries.
The Pharmaceutical segment counted for approximately 65% of total CRO services in 2020.
The statement “The Pharmaceutical segment accounted for approximately 65% of total Contract Research Organization (CRO) services in 2020” indicates that within the CRO industry, pharmaceutical companies were the dominant clients comprising the majority of services rendered. This statistic highlights the significant reliance of the CRO sector on pharmaceuticals and underscores the importance of pharmaceutical companies as key contributors to the revenue and growth of CRO firms. By capturing nearly two-thirds of the total services provided, pharmaceuticals played a central role in driving the activities and income of CROs in 2020. This data suggests a strong partnership and dependence between the pharmaceutical and CRO sectors, showcasing the mutual benefit derived from their collaboration.
The small and mid-size CROs are growing by nearly 15% every year.
The statistic that small and mid-size Clinical Research Organizations (CROs) are experiencing a growth rate of approximately 15% annually indicates a significant trend within the industry. This growth suggests that these smaller CROs are gaining traction and expanding their market share, potentially due to factors such as increased outsourcing of clinical trials by pharmaceutical companies, the demand for specialized services, and a focus on personalized medicine. Additionally, this growth rate may also reflect the ability of smaller CROs to provide more personalized and agile services compared to larger competitors. Overall, this statistic points towards a positive trajectory for small and mid-size CROs, highlighting their increasing importance and impact within the clinical research landscape.
The global preclinical CRO market is highly fragmented as the top 5 vendors accounted for only 23% of the total market share.
This statistic regarding the global preclinical CRO (Contract Research Organization) market indicates that the industry is characterized by a high level of fragmentation, with a large number of players competing for market share. The fact that the top 5 vendors together account for only 23% of the total market share highlights the absence of a single dominant player or a small group of major companies exerting significant control over the market. This scenario suggests that competition is fierce and that there is a diverse range of vendors offering preclinical CRO services, catering to different niches and client needs within the industry. The fragmentation in the market may also indicate opportunities for smaller or niche players to thrive alongside larger competitors, potentially driving innovation and specialization in the preclinical CRO sector.
On average, Phase 0 studies account for approximately 5% of overall preclinical work.
This statistic indicates that, on average, Phase 0 studies represent about 5% of all preclinical work conducted in the drug development process. Phase 0 studies usually involve very small groups of human subjects and focus on determining the pharmacokinetics and pharmacodynamics of a drug candidate in the human body. Despite being a small percentage of the preclinical work, Phase 0 studies play a crucial role in providing valuable data on how the drug candidate behaves in humans, setting the stage for subsequent phases of clinical trials. This statistic underscores the importance of these early human trials in the overall drug development process.
Pharmaceutical spending on preclinical development has risen by 8.3% year on year.
The statistic states that spending on the preclinical development phase of pharmaceutical research has increased by 8.3% each year. Preclinical development involves the initial stages of testing a drug candidate before it can progress to clinical trials in humans. This increase in spending indicates a growing investment in research and development within the pharmaceutical industry to advance potential new drugs towards eventual market approval. The rise in funding suggests a commitment to innovation and the pursuit of new treatments, potentially leading to the discovery of novel therapies that could address unmet medical needs and improve patient outcomes in the future.
China’s preclinical CRO market is growing at a compound annual growth rate (CAGR) of 27.03%
The statistic indicates that China’s preclinical Contract Research Organization (CRO) market is experiencing rapid growth, with a compound annual growth rate (CAGR) of 27.03%. This means that on average, the market size for preclinical CRO services in China is increasing by 27.03% each year. Such high growth rate suggests a strong demand for preclinical CRO services in China, likely driven by factors such as increasing outsourcing of research activities by pharmaceutical and biotechnology companies, advancements in the healthcare sector, and regulatory changes that promote innovation and investment in the life sciences industry. This growth rate also highlights the opportunity for both domestic and international preclinical CRO companies to capitalize on the expanding market in China.
The medical device segment market size was valued at USD 847.3 million in 2019.
The statistic ‘The medical device segment market size was valued at USD 847.3 million in 2019’ indicates the total worth of the market for medical devices in 2019. This value represents the combined revenue generated from the sales of medical devices within a specific time period, reflecting the demand for medical devices and the financial performance of companies operating in this industry. The market size figure of USD 847.3 million provides insight into the scale and economic significance of the medical device segment, serving as a key indicator for stakeholders such as investors, healthcare providers, policymakers, and researchers to assess the state and growth potential of the medical device market.
As per the statistics, by 2026, Asia-Pacific is expected to observe the fastest growth in the preclinical CRO services market.
This statistic indicates that based on current trends and forecasts, the Asia-Pacific region is anticipated to experience the most rapid expansion in the preclinical Contract Research Organization (CRO) services market by the year 2026. This growth could be attributed to various factors such as the increasing demand for preclinical services, advancements in research and development activities, rising investments in healthcare infrastructure, and the presence of a skilled workforce in the region. As a result, companies operating in the preclinical CRO services industry may find lucrative opportunities in the Asia-Pacific market, prompting them to allocate resources and expand their presence in this region to capitalize on the projected growth potential.
The Asia-Pacific preclinical CRO market is projected to be worth USD 1.75 Billion by 2026.
The statistic that the Asia-Pacific preclinical CRO market is projected to be worth USD 1.75 billion by 2026 indicates the estimated value of the market for contract research organizations (CROs) offering preclinical research services in the Asia-Pacific region by that year. This projection suggests significant growth opportunities in the preclinical CRO sector in the Asia-Pacific region, driven by factors such as increasing outsourcing of research and development activities by pharmaceutical and biotechnology companies, advancements in research technologies, and the growing demand for cost-effective and efficient drug development solutions. The market value of USD 1.75 billion highlights the potential size and importance of the Asia-Pacific preclinical CRO market in the global research and development landscape.
The number of preclinical CROs has increased by approximately 15% in the last 5 years.
The statistic ‘The number of preclinical CROs has increased by approximately 15% in the last 5 years’ indicates that there has been a notable growth in the quantity of preclinical Contract Research Organizations (CROs) over the specified time period. This increase of 15% suggests a significant expansion within the industry, demonstrating a trend of rising demand for outsourcing preclinical research services. Such a statistic may point towards various factors such as advancements in drug development, increased complexity of preclinical studies, and a shifting focus towards outsourcing to specialized service providers. This rise in the number of preclinical CROs could potentially impact competitiveness within the market, influence service quality, and provide more options for companies seeking preclinical research partners.
the infection segment of the preclinical CRO market is predicted to grow at a CAGR of around 8.7% during the forecast period of 2020 to 2025.
This statistic indicates that the infection segment within the preclinical Contract Research Organization (CRO) market is projected to experience a Compound Annual Growth Rate (CAGR) of approximately 8.7% from the year 2020 to 2025. This forecast suggests that there will be a steady and significant increase in demand for preclinical research services related to infections over the specified timeframe. Factors such as the rising prevalence of infectious diseases, advancements in research and development technologies, and increasing investments in drug development for infectious conditions are likely driving this growth trend. Stakeholders in the preclinical CRO industry can use this information to anticipate market opportunities, make informed business decisions, and develop strategies to capitalize on the expanding infection segment.
Europe held the second-largest revenue share in the preclinical CRO market, with nearly 30% in 2019.
In 2019, Europe accounted for the second-largest proportion of revenue in the preclinical Contract Research Organization (CRO) market, securing approximately 30% of the total share. This statistic indicates that Europe plays a significant role in the preclinical CRO industry, trailing behind the leading region in revenue generation. The substantial revenue share highlights Europe’s strong presence and competitiveness in providing preclinical research services to pharmaceutical, biotechnology, and medical device companies. It also suggests that European CROs are preferred partners for conducting preclinical studies, positioning the region as a key player in advancing drug discovery and development initiatives globally.
Department of Defense (DoD) funding for preclinical CROs increased by 5.6% in Fiscal Year (FY) 2021.
The statistic indicates that the funding provided by the Department of Defense (DoD) for preclinical Contract Research Organizations (CROs) experienced a rise of 5.6% in Fiscal Year (FY) 2021 compared to the previous year. This increase suggests that the DoD has allocated a greater budget towards supporting research conducted by preclinical CROs, which are typically involved in developing and testing new drugs, treatments, or technologies before they advance to clinical trials. The boost in funding could signify a heightened emphasis on advancing military-related medical research, enhancing collaborations with external research partners, or prioritizing innovation in defense-related technologies within the DoD research and development budget for the year.
The Latin America preclinical CRO market is expected to represent over 5% growth from 2020 to 2026.
This statistic indicates that the Latin America preclinical Contract Research Organization (CRO) market is projected to experience a growth rate of over 5% between 2020 and 2026. This growth suggests a positive trajectory for the industry in the region, reflecting an increasing demand for preclinical research services within the Latin American market. Factors driving this growth may include advancements in healthcare technologies, the rise in collaboration between pharmaceutical companies and CROs, and the attractiveness of the region for conducting preclinical trials. The forecasted growth signifies potential opportunities for CROs operating in Latin America to expand their services and capabilities, catering to the evolving needs of the pharmaceutical and biotechnology sectors in the region.
References
0. – https://www.www.reportsnreports.com
1. – https://www.www.transparencymarketresearch.com
2. – https://www.www.alliedmarketresearch.com
3. – https://www.www.gminsights.com
4. – https://www.www.verifiedmarketresearch.com
5. – https://www.www.meticulousresearch.com
6. – https://www.www.prnewswire.com
7. – https://www.www.futuremarketinsights.com
8. – https://www.www.marketsandmarkets.com
9. – https://www.www.globenewswire.com
10. – https://www.www.clinicalleader.com
11. – https://www.www.federalregister.gov
12. – https://www.www.fortunebusinessinsights.com
13. – https://www.en.people.cn
14. – https://www.www.researchandmarkets.com
15. – https://www.www.marketdataforecast.com
